Hypoglycemia.
Treat fast. Recheck. Find the cause. Definitions, the bedside fork (airway → access), pharm vs non-pharm etiologies, recurrent hypoglycemia workup, and discharge planning.
Reviewed June 2026 · verify against current guidelines
Diagnosis & Workup
Classify. Find the cause.
Symptom, not a diagnosis
Find the cause before the next dose. Untreated etiology means recurrent events. Adjust the regimen before discharge.
ADA classification (2026)
| Level 1 | BG 54–69 mg/dL (≤70 = alert value). Fast carb; hold or adjust glucose-lowering med. |
|---|---|
| Level 2 | BG <54 mg/dL. Treat now. Neuroglycopenia; higher mortality risk. |
| Level 3 | Any BG with altered status requiring assistance. IV or IM/IN glucagon. |
Treat below 70. Treat fast below 54.
BG blood glucoseIM/IN intramuscular / intranasal
Acute Management
Treat by scenario.
First-line by scenario
| Awake, swallowing safely | 15 g fast carb PO (4 oz juice, 3–4 glucose tabs). Rule of 15: recheck 15 min, repeat to BG ≥70, then complex-carb meal. |
|---|---|
| NPO or BG <54, IV access | D50 25 g IV (1 amp = 50 mL) over 2–5 min. D10 200 mL (20 g) is an alternative with less rebound. Recheck 15 min. |
| Altered / unresponsive, no IV | Glucagon 1 mg IM/SC or 3 mg intranasal. Place IV ASAP, then D50. Fails if glycogen depleted. |
| Sulfonylurea-induced (any severity) | D50 PRN + octreotide 50–100 mcg SC q8h. Admit: effect outlasts dextrose. Recheck q1–2h × 12–24h. |
Sulfonylurea hypoglycemia is admit-worthy. One D50 amp will fail.
PO by mouthD50/D10 50% / 10% dextrose in waterPRN as neededSC subcutaneous
Difficult Cases
Refractory hypoglycemia.
Dextrose alone fails or hypoglycemia recurs. Usually long-acting insulin or sulfonylurea overdose, or adrenal insufficiency. ICU care; call endocrine, toxicology, and poison control.
Long-acting insulin overdose
| Infusion | D10W 100–200 mL/h. Titrate to BG 100–180. May need 7+ days after a massive overdose. |
|---|---|
| Monitor | BG q30–60 min, then q1–2h once stable. Continuous K+; check Na+ daily. |
| Octreotide | Consider 50–100 mcg SC q8h. Blunts dextrose-driven endogenous insulin. Thin, case-level evidence in insulin overdose. |
| Steroids | Stress-dose hydrocortisone (e.g. 100 mg IV q8h) as last-resort adjunct. Case-report evidence. |
Don't stop dextrose early. Glargine effect can last 96+ h; recurrence is common. Replete K+ aggressively and watch Na+ (free-water load). Do not excise the injection-site depot.
D10W 10% dextrose in waterK+ potassiumNa+ sodium
Pitfalls
What gets missed.
Don't miss
- Sulfonylurea hypoglycemia is admit-worthy. Discharge after one D50 amp will fail.
- Hypoglycemia in sepsis predicts mortality. Escalate; don't just feed glucose.
- Glucagon needs glycogen. Fails in alcohol use, malnutrition, fasting, or liver failure.
- Give thiamine before glucose in alcohol use or malnutrition.
- Recheck BG q15min until stable, then scheduled monitoring.
- Find and document the cause; adjust the regimen before discharge.
One correction is rarely enough. Recheck before you assume it held.
BG blood glucose
Prevention
Prevent the next event.
Inpatient events recur. Fix the regimen before the next dose.
Inpatient adjustments (expert convention)
| NPO / poor PO | Hold prandial insulin. Reduce basal ~20–30%. Hold sulfonylureas. Keep correction scale. |
|---|---|
| AKI / renal | Clearance falls if eGFR <60. Reduce basal 25–50%. Stop sulfonylureas. Hold metformin. |
| Tube feeds off | Match basal to feeds. If feeds stop, start D10. |
| Steroid taper | Insulin requirement falls as steroids taper. Cut dose ~20%. Recheck BG TID. |
| After a hypo event | Reduce total daily dose ~20%. More if severe. |
AKI acute kidney injuryeGFR estimated GFRBG blood glucoseTID three times daily
Sources
Verify against current guidelines and local protocol before acting.
- ADA. Standards of Care in Diabetes 2026. Diabetes Care 2026;49(Suppl 1) (Level 1 = 54–69; Level 2 <54 mg/dL).
- McCall AL et al. Management of Individuals With Diabetes at High Risk for Hypoglycemia. Endocrine Society. J Clin Endocrinol Metab 2023;108(3):529–562.
- Cryer PE et al. Evaluation and Management of Adult Hypoglycemic Disorders. Endocrine Society Clinical Practice Guideline 2009.
- Fasano CJ et al. D10 vs D50 for ED hypoglycemia. Ann Emerg Med 2008 (less rebound, equivalent time to recovery).
- Glatstein M et al. Octreotide for sulfonylurea-induced hypoglycemia. Pediatr Emerg Care 2012.
- Demidowich AP et al. Prevention and Management of Insulin-Associated Hypoglycemia in Hospitalized Patients. Endocr Pract 2018 (≈20% TDD reduction after an event).
- FDA prescribing information: glucagon for injection (1 mg IM/SC/IV); intranasal glucagon (3 mg).
Downloads
Every card for this topic — carousels and tables, print-ready for the wards or for sharing.
